A Re-Examination of Physostigmine-Induced Cerebral Protection in the Hypoxic Mouse

A Critical Assessment of the Model

ALAN A. ARTRU, M.D. AND JOHN D. MICHENFELDER, M.D.

SUMMARY Using the hypoxic (FiO₂ = 0.05) mouse model as originally described, the survival time following pretreatment with physostigmine was examined. The maximum increase in survival time was 87% following a physostigmine dose of 0.4 mg/kg. This increase was considerably less than that previously reported for this drug in a hypoxic mouse study wherein the standard method for exposing mice to hypoxia was altered. We speculate that this alteration in methodology resulted in small variations in FiO₂ sufficient to account for the differences between these studies.

PHYSOSTIGMINE has recently been reported to provide cerebral protection in the hypoxic (FiO₂ = 0.05) mouse. At the maximally protective dose (0.3 mg/kg) survival was increased by 542% (survival time in controls was 4.3 min) and 4 of 14 animals survived more than one hour. These increases in survival are strikingly greater than any previously observed with this model for a variety of cerebral protective agents (barbiturates, anticonvulsants, anesthetics) or conditions (hypothermia, hypercarbia) either singly or in combination.

Though the hypoxic mouse model is based on a simple concept it is known to be quite sensitive to a number of variables, most importantly FiO₂. Accordingly, it is desirable for experimental animals to be tested simultaneously with control animals in the same hypoxic environment. By this means any unintended variation in FiO₂ will be recognized by abnormal survival times in the controls. In the aforementioned physostigmine study individual control or experimental mice were sequentially introduced into a single test chamber. This modification may have introduced unrecognized variations in FiO₂ resulting in altered survival times. The present study was designed to re-examine the increase in survival afforded by physostigmine using standard conditions for this model. We also examined the effect of both temperature and elapsed time from injection of the drug, two other conditions that may alter survival times.

Method

Subjects were 170 white male ARS HA/ICR albino mice (Sprague Dawley, Madison, WI) (weights 24-32 g) given free access to food pellets and tap water. Groups of 5 mice were weighed individually then injected intraperitoneally with either physostigmine (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7 mg/kg), an equal volume of 0.9% saline (controls), or pentobarbital (PTB) 50 mg/kg (controls). The injected volume ranged from 0.24 cc to 0.64 cc. Ten minutes later one animal was placed in each of 5 inter-connected airtight compartments breathing room air supplied at 4 L/min for an additional 10 min of temperature equilibration. The compartments were kept in a versa-range test chamber (Blue-M Engineering Co., Division of Blue-M Electric Co., Blue Island, IL) which, at ambient temperature of 35°C, maintained mouse intraperitoneal temperature at 37.0 ± 0.2°C. At the onset of each test period the room air gas supply was replaced by a mixture of N₂, 8-8.5 L/min and 5.22% O₂ (by Haldane analysis) in N₂, 15 L/min. Ten minutes later one animal was placed in each of 5 inter-connected airtight compartments breathing room air supplied at 4 L/min for an additional 10 min of temperature equilibration.

The compartments were kept in a versa-range test chamber (Blue-M Engineering Co., Division of Blue-M Electric Co., Blue Island, IL) which, at ambient temperature of 35°C, maintained mouse intraperitoneal temperature at 37.0 ± 0.2°C. At the onset of each test period the room air gas supply was replaced by a mixture of N₂, 8-8.5 L/min and 5.22% O₂ (by Haldane analysis) in N₂, 15 L/min. Ten minutes later one animal was placed in each of 5 inter-connected airtight compartments breathing room air supplied at 4 L/min for an additional 10 min of temperature equilibration.

From the Mayo Medical School, Rochester, MN. Dr. Artru is a Fellow in Anesthesiology, Dr. Michenfelder is Professor in Anesthesiology.

Supported in part by Research Grant NS-7507 from the National Institute of Health, Public Health Service.

Reprints: Dr. Michenfelder, Dept. Anesthesiology, Mayo Clinic, 200 First St., SW, Rochester, MN 55901.
Results

Under standard conditions the mean survival times observed for each group pretreated with physostigmine as well as for the saline and PTB 50 mg/kg pretreated control groups are shown in Table 1. The survival time of the saline treated controls (3.93 ± 0.07 min [mean ± sem]) was not different from that observed in previous studies employing the same model. Likewise, the survival time of the group pretreated with PTB 50 mg/kg did not differ from that observed in a previous study employing this model.86 Likewise, the survival time of the group pretreated with physostigmine 0.3 mg/kg was studied at a chamber temperature of 25°C, previously shown to result in mouse intraperitoneal temperature of 35°C. Survival data were subjected to analysis of variance. Where variance was confirmed further comparisons were made with Student's t-test for unpaired samples.

Table 1: Effect of Physostigmine Dose on Survival Time
(mean ± SEM), 37°C, 80 Min Drug Exposure

<table>
<thead>
<tr>
<th>Dose</th>
<th>N</th>
<th>Minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>50</td>
<td>3.93 ± 0.07†</td>
</tr>
<tr>
<td>PTB 50 mg/kg</td>
<td>10</td>
<td>13.99 ± 0.75†</td>
</tr>
<tr>
<td>Physostigmine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1 mg/kg</td>
<td>10</td>
<td>5.02 ± 0.41††</td>
</tr>
<tr>
<td>0.2 mg/kg</td>
<td>10</td>
<td>5.04 ± 0.29††</td>
</tr>
<tr>
<td>0.3 mg/kg</td>
<td>10</td>
<td>6.27 ± 0.31††</td>
</tr>
<tr>
<td>0.4 mg/kg</td>
<td>10</td>
<td>7.33 ± 0.46††</td>
</tr>
<tr>
<td>0.5 mg/kg</td>
<td>10</td>
<td>7.04 ± 0.44††</td>
</tr>
<tr>
<td>0.6 mg/kg</td>
<td>10</td>
<td>6.11 ± 0.33††</td>
</tr>
<tr>
<td>0.7 mg/kg</td>
<td>8</td>
<td>5.21 ± 0.29††</td>
</tr>
</tbody>
</table>

*Values represent only 8 animals; 2 animals died apneic prior to exposure to hypoxia.
†Significant difference from saline treated controls p < .001.
††Significant difference from PTB treated controls p < .001.

Table 2: Effect of Time of Drug Exposure and Temperature on Survival Time (mean ± SEM), Physostigmine, 0.3 mg/kg

<table>
<thead>
<tr>
<th>Drug Exposure</th>
<th>N</th>
<th>Minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 min</td>
<td>10</td>
<td>6.27 ± 0.31††</td>
</tr>
<tr>
<td>10 min</td>
<td>10</td>
<td>6.75 ± 0.49††</td>
</tr>
<tr>
<td>40 min</td>
<td>10</td>
<td>4.29 ± 0.09††</td>
</tr>
<tr>
<td>20 min</td>
<td>10</td>
<td>8.01 ± 0.51††</td>
</tr>
</tbody>
</table>

*Significantly different survival time (p < .001) than that for 20 min saline exposure, 37°C. In these hypothalamic controls (N = 10) survival time was 5.50 ± 0.36 min (mean ± SEM), which was significantly different than that for normothermic saline controls (p < .001).
†Significant difference from saline treated controls p < .02.
††Significant difference from PTB treated controls p < .001.

Discussion

It is likely that any protection afforded by physostigmine in this model is secondary to a drug induced increase in cerebral blood flow.8,8 The
neither a reduction in ambient temperature nor an alteration in drug exposure time sufficiently altered survival time to account for the differences between our study and that of Scremin and Scremin. We believe that the present study achieved standard conditions for this model since the survival times for both saline treated and PTB 50 mg/kg controls matched those of previous studies (see Results). Since the PTB-treated animals were tested simultaneously with the physostigmine-treated animals we are certain that the model as we used it was capable of demonstrating survival times greater than those observed in the physostigmine-treated groups.

The variable to which this model is most sensitive remains \( \text{FiO}_2 \), as reported by Secher and Wilhjelm. The figure is redrawn from their data with the inclusion of data from more recent reports from this laboratory. It shows the dramatic change in survival time that occurs with small changes in \( \text{FiO}_2 \). Since the curve for the protective agent (in this case thiopental) is shifted to the left of the control (saline treated) curve, any \( \text{FiO}_2 \) can be selected where small changes in \( \text{FiO}_2 \) (<0.005) will only modestly alter control survival while dramatically altering survival in the protected group. It seems likely that this effect could account for the differences between our data and that of Scremin and Scremin. If reproducible results are to be achieved with this model, it is necessary that experimental animals always be observed simultaneously with controls exposed to the same environment, that the \( O_2 \) concentration in the gases supplying the compartments is precisely determined, that total gas flows to the chamber and equilibration times are exactly reproduced from one series of animal exposures to the next, and that the \( O_2 \) concentration achieved in each compartment is monitored. Attention should also be given to the other variables reported to alter survival time when using this model, namely variations in \( CO_2 \) concentration and temperature.

![Figure](image_url)

**FIGURE.** Survival time for saline and barbiturate pretreated mice is plotted with respect to \( \text{FiO}_2 \). In the saline pretreated group small changes in \( \text{FiO}_2 \) when \( \text{FiO}_2 \) is near 0.05 produce only small changes in survival time. In barbiturate pretreated mice the survival curve is shifted upwards and to the left. When \( \text{FiO}_2 \) is near 0.05, small changes in \( \text{FiO}_2 \) now produce large changes in survival time.

Reference

5. Artru AA, Michenfelder JD: Cerebral protective, metabolic, and vascular effects of diphenylhydantoin. Submitted for publication.
A re-examination of physostigmine-induced cerebral protection in the hypoxic mouse. A critical assessment of the model.
A A Artru and J D Michenfelder

Stroke. 1980;11:197-199
doi: 10.1161/01.STR.11.2.197

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/11/2/197

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/